X0306 4 2014-12-09 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001394875 Labrucherie Gil M C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 0 1 0 0 SVP & General Counsel Stock Option 16.31 2014-12-09 4 A 0 87500 0.00 A 2022-12-08 Common Stock 87500 87500 D Stock Option 16.31 2014-12-09 5 A 0 E 87500 0.00 A 2022-12-08 Common Stock 87500 87500 D This option was granted on December 9, 2014 and vests in monthly installments over the four-year period following the grant date. This stock option is subject to both time-based vesting and performance-based vesting conditions, both of which must be met before the shares subject to the option become vested and exerciseable. The time-based vesting is on a monthly pro-rata basis over a period of 4 years from the grant date (December 9, 2014). The performance-based vesting condition will be met only if Nektar (or a licensee) files, within five years following the grant date, a new drug registration with the FDA or the European Medicines Agency for a significant drug candidate program (average royalty >7.5%) including, without limitation, the following: (1) etirinotecan pegol; (2) NKTR-061/Amikacin Inhale; (3) Ciprofloxacin Dry Powder for Inhalation; or (4) NKTR-181 (an oral opioid analgesic drug candidate). Gilbert M. Labrucherie, Jr. 2014-12-11